Aveo Oncology is not letting a high-profile rejection get it down.

In the wake of a cancer drug rejection, the biotech company is plotting a comeback, the Boston Business Journal reports.

BBJ's Don Seiffert said the Cambridge, Massachusetts-based company's kidney cancer drug was rejected because "the overall survival rate wasn't impressive enough for the FDA."

Learn more in the video above.